Dr. Hellmann on Tumor Mutational Burden Testing in Patients With Lung Cancer

Matthew D. Hellmann, MD
Published: Friday, May 11, 2018



Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Physicians have increasingly started to visualize lung cancer as a pie chart in which patients are defined by their distinct biology. EGFR, ALK, RET, ROS1, and BRAF are all examples of identified molecular markers that specific therapies can target.

Although TMB might sound as if it's a separate test, Hellman says it is actually additional data physicians get from the routine molecular analysis, which should be done in all patients with lung cancer. Molecular profiling has enabled physicians to understand both molecular aberrations and TMB. This ultimately brings a new piece of the pie that contains specific therapy indications with exceptional opportunity for long-term benefit, says Hellman.
 


Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Physicians have increasingly started to visualize lung cancer as a pie chart in which patients are defined by their distinct biology. EGFR, ALK, RET, ROS1, and BRAF are all examples of identified molecular markers that specific therapies can target.

Although TMB might sound as if it's a separate test, Hellman says it is actually additional data physicians get from the routine molecular analysis, which should be done in all patients with lung cancer. Molecular profiling has enabled physicians to understand both molecular aberrations and TMB. This ultimately brings a new piece of the pie that contains specific therapy indications with exceptional opportunity for long-term benefit, says Hellman.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x